Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...
“DESTINY-Breast11 results support T-DXd [plus] THP as a more effective and less toxic neoadjuvant treatment compared with ddAC-THP, and it may become the preferred regimen for patients with high-risk, ...
The mixture is then placed in an RT–PCR machine. The machine cycles through temperatures that heat and cool the mixture to trigger specific chemical reactions that create new, identical copies of the ...
A 1985 prototype of a semi-automated thermal cycler, hot and cold water baths not included. Credit: Courtesy of The Smithsonian Institution" />A 1985 prototype of a semi-automated thermal cycler, hot ...
MedPage Today on MSN
Trastuzumab Deruxtecan Scores Two Wins in HER2-Positive Early Breast Cancer
B ERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in ...
A phase 2 trial evaluated the combination of neoadjuvant pembrolizumab and accelerated methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in patients with nonurothelial bladder cancers ...
To our knowledge, SunRISe-4 shows, for the first time, a benefit of the addition of the localised TAR-200 gemcitabine intravesical system to systemic checkpoint inhibition as neoadjuvant treatment in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback